Navigation Links
Martek to Present at Upcoming Canaccord Adams Conference
Date:7/28/2009

COLUMBIA, Md., July 28 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK) announced today that it will be presenting at the Canaccord Adams 29th Annual Global Growth Conference which is scheduled to take place August 11-13, 2009 at the InterContinental Boston Hotel in Boston, MA. Steve Dubin, Chief Executive Officer, and Peter L. Buzy, Chief Financial Officer, are scheduled to present on Tuesday, August 11, 2009, at 3:00 p.m. Eastern Time.

A live audio webcast of Martek's presentation can be accessed at:

http://www.wsw.com/webcast/canaccord/matk/

Martek Biosciences Corporation is a leader in the innovation and development of omega-3 DHA products that promote health and wellness through every stage of life. The Company produces life'sDHA(TM), a vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, infant formula and supplements, and life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, for use in infant formula. For more information on Martek Biosciences, visit http://www.martek.com.

    Contact: Kyle Stults
             Investor Relations
             (410) 740-0081


'/>"/>
SOURCE Martek Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Martek Announces Second Quarter 2009 Financial Results
2. Martek Signs Sole-Source ARA Supply Agreement with Lactalis Nutrition Sante
3. Martek, March of Dimes Partner to Promote Importance of DHA
4. Martek and Ragasa Sign Multi-Year Exclusive Supply Agreement
5. Martek to Announce First Quarter 2009 Results
6. Marteks lifesDHA(TM) Featured in Four New Products from Spectrum Organics
7. Marteks lifesDHA(TM) Now Available in Rachels(TM) Yogurt at Grocery Retailers Nationwide
8. Martek to Present at Upcoming Needham Conference
9. Australias Leading Juice Company Launches Juice Blend with Marteks lifesDHA(TM)
10. Sunkist Naturals Glorious Greens Smoothie Features Marteks lifesDHA
11. Martek Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... MA (PRWEB) , ... December 08, 2016 , ... ... Workers Compensation Research Institute (WCRI) officially opened registration today for its 33rd ... Hotel in Boston, MA . , The theme of the conference is “Persistent ...
(Date:12/8/2016)... PLAINS, N.Y., and JENNERSVILLE, Pa. (PRWEB) , ... ... ... to announce that Penn Medicine Southern Chester County, a Property owned by an ... The $23 million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care ...
(Date:12/8/2016)... , ... December 08, 2016 , ... With the increasing ... the “What’s In Your Mouth?” (WIYM) campaign to inform dentists and patients about the ... the dental implant and prosthetic market in the U.S. is projected to reach $6.4 ...
(Date:12/8/2016)... ... 08, 2016 , ... SunView Software aims to redefine IT ... both engaging and easy to use. Coming off the heels of a successful ... its plans to roll out new AI-powered self-service enhancements to help organizations implement ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ... been recognized for adherence to the highest standards of trauma, maternity, cancer and ... the center's president and CEO, Dr. Daniel Messina. , Among the recognitions, the ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  A Mederi Therapeutics Inc . anunciou aprovação regulatória, pela CFDA, e ... doença do refluxo gastroesofágico (DRGE). Foto -  http://photos.prnewswire.com/prnh/20161207/446903 ... ... Live Stretta procedure performed and broadcast during the Chinese Congress of Digestive Endoscopy, ... , , ...
(Date:12/8/2016)... CITY , Dec. 8, 2016 ... US patents for improving the accuracy, reproducibility and ... images in long and small bone orthopaedic applications. ... approach to creating personalized orthopaedic restorations based on ... personalized orthopaedic restorations, the company harnesses the world,s ...
(Date:12/8/2016)... 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... announced positive results from a Phase 3, multicenter ... safety and efficacy of IDP-118 (halobetasol propionate and ... Within the Phase 3 study ... psoriasis, IDP-118 showed statistical significance to vehicle with ...
Breaking Medicine Technology: